# Enzalutamide in Combination With PSA-TRICOM in Patients With Non-Metastatic Castration Sensitive Prostate Cancer

> **NCT01875250** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 38 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **BIOLOGICAL:** PROSTVAC-F (Fowlpox)/TRICOM
- **BIOLOGICAL:** PROSTVAC-V (Vaccinia)/TRICOM
- **DRUG:** Enzalutamide (Xtandi)

## Key facts

- **NCT ID:** NCT01875250
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-07-22
- **Primary completion:** 2019-09-01
- **Final completion:** 2020-02-28
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2020-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01875250

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01875250, "Enzalutamide in Combination With PSA-TRICOM in Patients With Non-Metastatic Castration Sensitive Prostate Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01875250. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*